398 related articles for article (PubMed ID: 20880751)
1. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
Calabresi P; Di Filippo M; Ghiglieri V; Tambasco N; Picconi B
Lancet Neurol; 2010 Nov; 9(11):1106-17. PubMed ID: 20880751
[TBL] [Abstract][Full Text] [Related]
2. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
[TBL] [Abstract][Full Text] [Related]
3. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
Thanvi B; Lo N; Robinson T
Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
[TBL] [Abstract][Full Text] [Related]
4. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptors and L-dopa-induced dyskinesia.
Berthet A; Bezard E
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S8-12. PubMed ID: 20123563
[TBL] [Abstract][Full Text] [Related]
6. Preventing levodopa-induced dyskinesias.
Olanow CW; Obeso JA
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
[TBL] [Abstract][Full Text] [Related]
8. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
Picconi B; Calabresi P
Mov Disord; 2014 May; 29(6):715-9. PubMed ID: 24591264
[TBL] [Abstract][Full Text] [Related]
9. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
Fiorentini C; Busi C; Spano P; Missale C
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S159-64. PubMed ID: 18638717
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
11. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
[TBL] [Abstract][Full Text] [Related]
12. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pathophysiologic aspects of late levodopa failure.
Poewe W
Neurology; 1993 Dec; 43(12 Suppl 6):S28-30. PubMed ID: 8264908
[TBL] [Abstract][Full Text] [Related]
14. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
Rascol O; Fox S; Gasparini F; Kenney C; Di Paolo T; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Sep; 20(9):947-56. PubMed ID: 24951359
[TBL] [Abstract][Full Text] [Related]
15. Motor complications associated with chronic levodopa therapy in Parkinson's disease.
Obeso JA; Grandas F; Vaamonde J; Luquin MR; Artieda J; Lera G; Rodriguez ME; Martinez-Lage JM
Neurology; 1989 Nov; 39(11 Suppl 2):11-9. PubMed ID: 2685647
[TBL] [Abstract][Full Text] [Related]
16. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Encarnacion EV; Hauser RA
Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
[TBL] [Abstract][Full Text] [Related]
17. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
Piccini P; Weeks RA; Brooks DJ
Ann Neurol; 1997 Nov; 42(5):720-6. PubMed ID: 9392571
[TBL] [Abstract][Full Text] [Related]
18. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
19. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
Cheshire PA; Williams DR
J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
[TBL] [Abstract][Full Text] [Related]
20. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.
Ahmed I; Bose SK; Pavese N; Ramlackhansingh A; Turkheimer F; Hotton G; Hammers A; Brooks DJ
Brain; 2011 Apr; 134(Pt 4):979-86. PubMed ID: 21371994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
